Why the push for government-negotiated drug prices could prove to be a Sisyphean task.
Drug-pricing reform an uphill battle
![](https://www.janushenderson.com/wp-content/uploads/sites/4/660x440_GettyImages-171585034.jpg?w=640)
Why the push for government-negotiated drug prices could prove to be a Sisyphean task.
Portfolio Manager and Head of Global Sustainable Equities, Hamish Chamberlayne explores the changes ahead as we enter a decade of transformation and explains the importance of digitalisation, electrification and decarbonisation.
We believe active managers are in a position to drive positive change amid the shift to sustainability.
John Bennett, Portfolio Manager of Henderson European Focus Trust, provides an update on the Trust’s recent performance and highlights the factors affecting the European market.
Why we believe active engagement is key to gauging companies’ progress on addressing environmental and social issues.
The Biden administration’s highly anticipated plan for drug-pricing reform includes proposals that could limit the private sector’s willingness to invest in future research. Portfolio Manager Andy Acker and Research Analyst Luyi Guo say investors shouldn’t count on that outcome just yet.
Monetary trends have yet to signal an end to the current economic slowdown phase, argues Simon Ward, Economic Adviser.
Why the push for government-negotiated drug prices could prove to be a Sisyphean task.
Why the push for government-negotiated drug prices could prove to be a Sisyphean task.
Research shows that receiving financial education from our parents can lead to improved financial behaviors.